6-[4-(1-methylpyrazol-4-yl)sulfonyl-1,4-diazepan-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine
C15H17F3N8O2S — CID 138988530
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-[4-(1-methylpyrazol-4-yl)sulfonyl-1,4-diazepan-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine
6-[4-(1-methylpyrazol-4-yl)sulfonyl-1,4-diazepan-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine (PubChem CID 138988530) has the molecular formula C15H17F3N8O2S and a molecular weight of 430.42 g/mol. Its IUPAC name is 6-[4-(1-methylpyrazol-4-yl)sulfonyl-1,4-diazepan-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine.
Molecular Properties
| Compound Name | 6-[4-(1-methylpyrazol-4-yl)sulfonyl-1,4-diazepan-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine |
|---|---|
| PubChem CID | 138988530 |
| Molecular Formula | C15H17F3N8O2S |
| Molecular Weight | 430.42 g/mol |
| Exact Mass | 430.11 |
| IUPAC Name | 6-[4-(1-methylpyrazol-4-yl)sulfonyl-1,4-diazepan-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine |
| SMILES | Cn1cc(S(=O)(=O)N2CCCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)cn1 |
| InChI | InChI=1S/C15H17F3N8O2S/c1-23-10-11(9-19-23)29(27,28)25-6-2-5-24(7-8-25)13-4-3-12-20-21-14(15(16,17)18)26(12)22-13/h3-4,9-10H,2,5-8H2,1H3 |
| InChIKey | BMPUDUFLIYSJLV-UHFFFAOYSA-N |
| XLogP | 0.78 |
| TPSA | 101.52 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 430.42 |
| LogP ≤ 5 | 0.78 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 138988530 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.